Akero Therapeutics, Inc. (NASDAQ:AKRO - Get Free Report) CEO Andrew Cheng sold 1,738 shares of Akero Therapeutics stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $78,001.44. Following the transaction, the chief executive officer now directly owns 654,324 shares in the company, valued at approximately $29,366,061.12. The trade was a 0.26 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Andrew Cheng also recently made the following trade(s):
- On Monday, March 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $41.77, for a total value of $1,253,100.00.
- On Monday, February 10th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $52.73, for a total value of $1,581,900.00.
- On Monday, January 27th, Andrew Cheng sold 30,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $54.90, for a total value of $1,647,000.00.
Akero Therapeutics Trading Down 2.9 %
Shares of Akero Therapeutics stock traded down $1.29 on Tuesday, reaching $43.53. The company had a trading volume of 770,345 shares, compared to its average volume of 812,716. The firm has a market cap of $3.47 billion, a price-to-earnings ratio of -11.61 and a beta of -0.19. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25. The firm's 50-day moving average price is $42.44 and its two-hundred day moving average price is $34.02. Akero Therapeutics, Inc. has a 1 year low of $17.86 and a 1 year high of $58.40.
Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last announced its earnings results on Friday, February 28th. The company reported ($0.99) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by ($0.01). As a group, research analysts predict that Akero Therapeutics, Inc. will post -3.99 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Akero Therapeutics
Large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. purchased a new position in Akero Therapeutics during the 4th quarter valued at $41,000. Sterling Capital Management LLC raised its position in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock worth $50,000 after acquiring an additional 1,582 shares in the last quarter. Quarry LP bought a new position in shares of Akero Therapeutics in the 4th quarter worth $83,000. Summit Investment Advisors Inc. raised its position in shares of Akero Therapeutics by 6.8% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock worth $197,000 after acquiring an additional 450 shares in the last quarter. Finally, Summit Financial Wealth Advisors LLC acquired a new position in Akero Therapeutics during the 3rd quarter valued at about $205,000.
Analysts Set New Price Targets
AKRO has been the topic of several recent analyst reports. Bank of America raised Akero Therapeutics from a "neutral" rating to a "buy" rating and lifted their target price for the company from $35.00 to $63.00 in a research note on Thursday, January 30th. Citigroup lifted their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. HC Wainwright lifted their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the stock a "buy" rating in a research note on Monday, March 3rd. UBS Group lifted their price objective on Akero Therapeutics from $42.00 to $109.00 and gave the stock a "buy" rating in a research note on Friday, January 31st. Finally, Canaccord Genuity Group lifted their price objective on Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research note on Tuesday, January 28th. Nine research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $76.29.
Check Out Our Latest Report on AKRO
About Akero Therapeutics
(
Get Free Report)
Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.
Further Reading
Before you consider Akero Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Akero Therapeutics wasn't on the list.
While Akero Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
